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Abstract
Background: The Michigan Prevention Research Center, the University of Michigan Schools of Nursing, Public
Health, and Medicine, and the Michigan Department of Community Health propose a multidisciplinary academic-
clinical practice three-year project to increase breast cancer screening among young breast cancer survivors and
their cancer-free female relatives at greatest risk for breast cancer.
Methods/design: The study has three specific aims: 1) Identify and survey 3,000 young breast cancer survivors
(diagnosed at 20–45 years old) regarding their breast cancer screening utilization. 2) Identify and survey survivors’
high-risk relatives regarding their breast cancer screening utilization. 3) Test two versions (Targeted vs. Enhanced
Tailored) of an intervention to increase breast cancer screening among survivors and relatives. Following approval
by human subjects review boards, 3,000 young breast cancer survivors will be identified through the Michigan
Cancer Registry and mailed an invitation letter and a baseline survey. The baseline survey will obtain information on
the survivors’: a) current breast cancer screening status and use of genetic counseling; b) perceived barriers and
facilitators to screening; c) family health history. Based on the family history information provided by survivors, we
will identify up to two high-risk relatives per survivor. Young breast cancer survivors will be mailed consent forms
and baseline surveys to distribute to their selected high-risk relatives. Relatives’ baseline survey will obtain
information on their: a) current breast cancer screening status and use of genetic counseling; and b) perceived
barriers and facilitators to screening. Young breast cancer survivors and high-risk relatives will be randomized as a
family unit to receive two versions of an intervention aiming to increase breast cancer screening and use of cancer
genetic services. A follow-up survey will be mailed 9 months after the intervention to survivors and high-risk
relatives to evaluate the efficacy of each intervention version on: a) use of breast cancer screening and genetic
counseling; b) perceived barriers and facilitators to screening; c) self-efficacy in utilizing cancer genetic and
screening services; d) family support related to screening; e) knowledge of breast cancer genetics; and f) satisfaction
with the intervention.
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Discussion: The study will enhance efforts of the state of Michigan surrounding cancer prevention, control, and
public health genomics.
Trial registration: NCT01612338
Keywords: Breast cancer screening, Familial breast cancer, Young breast cancer survivors, High-risk relatives,
Randomized trial, Targeted and enhanced tailored intervention, Screening mammography, Genetic testing, Cancer
registry, State-wide community-based sample
Background
Breast cancer is the second most common cancer among
U.S. women and the second leading cause of cancer
death [1]. One of the goals of the Comprehensive Cancer
Control Plan for Michigan is to further “reduce the fe-
male breast cancer death rate” [2]. This study strives to
contribute to this goal, specifically for female Young
Breast Cancer Survivors (YBCS) diagnosed at 20–45 years
old and their female relatives who may be at increased
risk.
Breast cancer survivors have a 2-fold higher risk of
developing a second breast cancer, compared to women
without breast cancer, matched for age, breast density,
and use of mammography [3]. In addition, unaffected
first- and second-degree relatives of women diagnosed
with breast cancer younger than 50 years of age have re-
spectively a 2.3 and 1.5 increased relative risk for breast
cancer [4]. The initial step in determining an unaffected
woman’s risk for breast cancer is the collection of a thor-
ough family history that includes first- and second-
degree relatives on both the maternal and paternal sides
of the family [5]. However, a review of health plan charts
conducted by the Genomics Program at the Michigan
Department of Community Health revealed that only
42% of charts had documented a family history of breast
cancer, while, 98% of these charts did not document age
of onset for the affected family members [6]. According
to national recommendations, women with a strong
family history of breast cancer should be referred for
genetic counseling [7,8]. Yet, a phone survey of the gen-
eral adult population living in Michigan revealed that
only 12% of high-risk women older than 40 years of age
actually received this service [6]. Furthermore, only 56%
of these high-risk women had a Clinical Breast Exam
(CBE) in the past 12 months; only 48% had a mammo-
gram in the past 12 months; and, only 44% had both a
mammogram and CBE in the past 12 months [6].
The study aims to increase breast cancer surveillance and
early detection by targeting YBCS identified from a state can-
cer registry and their high risk relatives. Specific aims are to:
Aim 1: Identify and survey 3,000 female YBCS
reported to the cancer registry who were diagnosed be-
tween the ages of 20–45 years and determine: (a) their
current breast cancer screening status; (b) perceived
barriers and facilitators to screening; (c) willingness to
participate in an intervention to increase breast cancer
screening; and (d) willingness to serve as a breast cancer
screening advocate for their high-risk relatives.
Aim 2: Identify and survey up to two unaffected first-
and/or second-degree female relatives per YBCS and de-
termine: (a) their current breast cancer screening status;
(b) perceived barriers and facilitators to screening; and
(c) willingness to participate in an intervention to in-
crease breast cancer screening. Female relatives will be
between 25–64 years and have an increased risk of
breast cancer based on the YBCS’ age of diagnosis.
Aim 3: Compare the efficacy of two versions of an
intervention on breast cancer screening utilization and
other outcomes among YBCS and their high-risk female
relatives. YBCS and their high-risk female relatives will
be randomly assigned as a family unit to receive either
the Targeted or the Enhanced Tailored version of the
intervention. (Description of the two intervention
methods follows).
Methods/design
This prospective, randomized trial involves testing the
efficacy of two versions of a printed intervention (i.e.,
Targeted version and Enhanced Tailored version).
Participants will be randomly assigned as family units
(YBCS and her high-risk female relatives) to receive one
of two versions. The survivor and relative(s) of enrolled
family units will be mailed a self-administered baseline
survey prior to receiving the intervention (Time 1). A
self-administered, follow-up survey will be mailed to YBCS
and high-risk relatives nine months post-intervention
(Time 2).
Setting
The Michigan Cancer Surveillance Program is a central
cancer registry that was established by law (Act 82 of
1984) [9] to collect reports on cases for in situ and inva-
sive malignancies. Between 1998 and 2007, there were
7,866 YBCSs identified in the Michigan Cancer Sur-
veillance Program [10]. This database will be used to
identify and recruit YBCS. The Michigan Department
of Community Health-Genomics Program and the Uni-
versity of Michigan-School of Nursing will enroll
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participating families, implement the two versions of the
intervention, and collect and analyze baseline (Time 1)
and follow up (Time 2) data.
Recruitment of YBCS and high-risk relatives
Between 1994 and 2008 there were 9,000 cases of young
women with breast cancer were reported to the
Michigan Cancer Registry. For the study, 3,000 women
diagnosed with invasive or in –situ-breast cancer be-
tween 20 to 45 years old from 1994 to 2008 will be ran-
domly selected from the cancer registry database. The
Michigan Cancer Surveillance Program will cross-
reference mortality data to exclude deceased YBCS. To
increase inclusion of minority and underserved women,
the sample will be stratified by race. The study will
oversample YBCS who are black and living in counties
with the highest mortality rates for young women with
breast cancer (See Figure 1).
As shown in Figure 2, it is estimated that from the ini-
tial 3,000 YBCS, approximately 1,200 will be willing to
participate (40% response rate). We estimate that ap-
proximately 20% of these YBCS (n = 240) will not have
any eligible high-risk female relatives (e.g. relatives will
be younger than 25 or older than 64). These YBCS will
be included in the study but will be analyzed as a separ-
ate group. Based on our previous experience recruiting
women with familial breast cancer and their high-risk
relatives [11], we project that the remaining 960 YBCS
will have approximately 1,728 eligible high-risk female
relatives. This estimation is based on the assumption
that we will be able to identify 1.8 first- and/or second-
degree, high-risk relatives per YBCS. Based on our previ-
ous experience [11], we expect that 604 high-risk
relatives will be willing to participate in the study (35%
response rate). Table 1 describes inclusion and exclusion
criteria for YBCS and high-risk female relatives.
Recruitment procedures will involve the following
steps:
1) Obtain approval to conduct research with human
subjects from the Institutional Review Boards at the
University of Michigan and at the Michigan
Department of Community Health, and the Scientific
Advisory Board of the Michigan Cancer Registry.
2) The cancer registry will send a letter to the reporting
facility and the physician of record asking if they are
aware of any reason that the YBCS should not be
contacted to participate in the study. The YBCS will
be excluded from the study if the reporting facility or
physician of record responds to this letter requesting
that the YBCS not be contacted.
3) If there is no reason to exclude YBCS, the cancer
registry will mail an invitation letter to the YBCS
requesting her participation in the study, along with
an Informed Consent form, and the self-
administered baseline survey. The invitation letter
and consent form will explain the study and state
that if the YBCS is currently incarcerated or
institutionalized, or if she is pregnant, she is not
eligible to participate. The invitation letter will
explain that these two conditions may interfere with
a woman being able to get breast cancer screening.
The invitation letter and consent form include
contact information for the Director of the cancer
registry and the Principal Investigator of the study,
and a toll-free phone number for the Michigan
Department of Community Health-Genomics
Program for the YBCS to ask further questions about
the study.
4) YBCS who agree to participate will return the signed
consent form and the completed baseline survey to
the cancer registry in a postage-paid, pre-addressed
envelope. There will be up to three mailed attempts
to reach non-responding YBCS. The cancer registry
will not release any identifiable information to the
research team until the YBCS mails back her signed
consent form and her baseline survey.
5) Once an YBCS agrees to participate, her contact
information and baseline survey will be released to
the Michigan Department of Community Health-
Genomics Program. Two board-certified genetic
counselors employed by the program will review all
Age-Adjusted Mortality Rates
Suppressed Rate
2.5 - 5.4
5.5 - 13.1
Age-Adjusted Ten-Year Mortality Rates for Breast Cancer
 by County among Women in Michigan, 
under age 50, 2000 - 2009  
Figure 1 Age-adjusted ten-year mortality rates for breast cancer
by county among women in Michigan under age 50, 2000–2009.
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returned surveys to ascertain YBCS eligibility. If the
YBCS reports being diagnosed with a known
hereditary cancer syndrome such as BRCA1, BRCA2,
Lynch, PTEN Hamartoma Tumor, Li-Fraumeni, or
Peutz-Jeghers syndromes, the genetic counselors will
contact her by phone and provide additional
information to raise awareness about appropriate
resources and clinical care. These YBCS (estimated
n = 100) will be excluded from Aim 3 of the study.
6) Based on information provided by the YBCS in the
baseline survey, the genetic counselors will identify
up to two high-risk relatives per YBCS. Eligible high-
risk relatives will be female, first- and/or second-
degree relatives, and unaffected by cancer.
Identification of high-risk relatives will be according
to a protocol that involves pedigree analysis.
Questions that assess family history of cancer allow
calculations of Gail [12] and Claus [13] risk models.
YBCS will be asked how many first and second
degree relatives had cancer, type of cancer, and age
of onset. Then YBCS are asked to list the first and
second degree relatives in the family who are cancer
free, their age, and whether they are willing to
contact them for the study. The combination of
answers in these two sets of questions allows genetic
counselors to identify eligible, high-risk relatives. As
explained in the informed consent form, if necessary,
the genetic counselors will contact the YBCS by
phone to obtain additional family history
information. Each participating YBCS will be mailed
a letter asking her to contact the identified high-risk
relatives and request their participation in the study.
Consent forms, baseline surveys and postage-paid
return envelopes will be provided to the YBCS to
give to her relatives. A “Project Navigator” will be
available by telephone to discuss any concerns the
YBCS may have about this procedure. If an identified
high-risk relative does not mail back her signed
consent form and completed baseline survey within
six to eight weeks, the Project Navigator will contact
the YBCS to determine if an alternate high-risk
relative should be selected for participation.
7) Relatives’ signed consents and completed baseline
surveys will be returned to the Michigan
Department of Community Health-Genomics
Program. This is the first time that the research
team will receive identifiable information from high-
risk relatives. The genetic counselors will review
relatives’ signed consent forms to further ascertain
eligibility for participation. After randomization, the
genetic counselors will also calculate objective breast
cancer risk for the high-risk relatives who will be
randomized to receive the Enhanced Tailored version
of the intervention. The Gail model [12] and the
Claus model [13] will be used to calculate these
objective risk estimates. Using two different risk
Figure 2 CONSORT diagram-flow of study participants. Est. = Estimated.
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estimation models is necessary because the Gail
model does not apply to women younger than
35 years of age.
8) YBCS and high-risk relatives will receive a check for
$10 in the mail when they return their baseline
survey and a check for $20 when they return their
follow-up survey.
Stratification and randomization
Before randomization, YBCS (with and without high-risk
relatives) will be stratified by self-reported race (black vs.
other) to ensure equal distribution of ethnic minority
participants across study arms. YBCS (n = 960 with
high-risk relatives and n = 240 without high-risk
relatives) will be randomly allocated to receive either the
Table 1 Eligibility criteria
Eligibility criteria for young breast cancer survivors Eligibility criteria for high-risk female relatives
• Female • Female
• 25–64 years of age • 25–64 years of age
• Being diagnosed with unilateral or bilateral invasive breast cancer between 20 and
45 years old
• Unaffected with any type of cancer
• Being diagnosed with unilateral or bilateral DCISж between 20 and 45 years old • First- or second-degree relatives of the YBCS
• Michigan resident at time of diagnosis • US resident
• Able to read and understand English • Able to read and understand English
• Not currently pregnant, incarcerated, or institutionalized* • Not currently pregnant, incarcerated, or
institutionalized*
• YBCS is willing to contact
ж Ductal Carcinoma In Situ.
* Women who are pregnant, incarcerated, or institutionalized at the time of the study are excluded because they may not be able to follow recommendations for
breast cancer screening and genetic counseling.
Perceived risk for breast CA
Knowledge
Risk factors Mammography Mammography
Genetics of breast CA CBE, Gen. couns. CBE
Perceived barriers to screening Genetic counseling
Perceived faci l i tators to screening
Perceived expectations of fami ly
members
Motivation to comply wi th fami ly
expectations
Self-efficacy use of screening
Key
Relationships in model
Effects of both interventions
Add'l effect of Enhanced Tailored intervention
Intention Screening Behavior
Knowledge / Attitudes
Subjective Norms
Family 
Support
INTERVENTION
Perceived Control
Figure 3 Expanded theory of planned behavior. CBE = Clinical Breast Exam.
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Targeted or the Enhanced Tailored version of the inter-
vention via a computerized program generated by the
study statistician. YBCS and high-risk relatives will be
randomly assigned as a family unit.
Targeted vs. enhanced tailored intervention
An expansion of the Theory of Planned Behavior (TPB)
[14] was used as the framework to guide the develop-
ment of the two versions of the intervention. The
expanded TPB includes two additional components that
are specific to the needs of YBCS and their high-risk
relatives. The first component is knowledge about breast
cancer risk factors and cancer genetics. The second
component is perceived family support regarding breast
cancer screening behaviors. Figure 3 shows the modified
version of the TPB and the constructs hypothesized to
be affected by the two versions of the intervention.
Development of the Targeted version is based on a
mailed intervention recommended by the Guide to
Community Preventive Services as efficacious in increas-
ing breast cancer screening among older, non-adherent
women [15]. Participants randomized to the Targeted
version will receive a personalized letter and a booklet
that addresses breast cancer screening and genetic coun-
seling in YBCS and high-risk relatives. The Enhanced
Tailored version of the intervention will provide tailored
information about 1) breast cancer risk; 2) adherence to
screening and perceived barriers; and 3) ways to enhance
family support related to breast cancer screening. Based
on participants’ responses to the baseline survey, the
study team will add evidence-based components to ad-
dress the specific needs of YBCS and their high-risk fe-
male relatives that will be randomized to receive the
Enhanced Tailored version. All the components that
comprise the two versions of the mailed intervention are
shown in Figure 4. All intervention materials are
developed at the 9th grade reading level or less.
Tailored health messages have the greatest advantage
over targeted messages when there is significant variabil-
ity within the targeted audience on key determinants of
the intended outcome, e.g., knowledge and attitudes
[16]. When there is little variability on the key
determinants of the intended outcome, targeting could
be as effective as tailoring and more cost-effective. In
the case of screening mammography, two meta-analyses
reported that although tailored interventions are more
efficacious compared to non-tailored ones in increasing
mammography screening [17,18], reminder-type, targeted
interventions could also be efficacious in promoting
repeated use of mammography [19]. Given that tailored
Targeted Intervention
Survivor Relatives
Letter: Letter:
Personalized with: Personalized with:
Participant’s name Participant’s name
Increased risk due to breast 
CA history
Increased risk due to family 
history of breast CA
NCCN guidelines for breast 
CA surveillance
NCCN guidelines for breast 
CA screening
Suggest genetic counseling
Booklet: Booklet: 
Mammogram Mammogram
Clinical breast exam Clinical breast exam
Genetic counseling Genetic counseling
Low cost screening Low cost screening
Enhanced Tailored Intervention
Survivor Relatives
Letter: Letter:
Personalized with: Personalized with:
Participant’s name Participant’s name
Increased risk due to breast  
CA history
Increased risk due to family 
history of breast CA
NCCN guidelines for breast 
CA surveillance
NCCN guidelines for breast 
CA screening
Tailored on: Tailored on: 
Adherence to surveillance Adherence to screening
Barriers Barriers
Objective risk (Gail/ Claus)
Perceived risk
Booklet: Booklet: 
Mammogram Mammogram
Clinical breast exam Clinical breast exam
Genetic counseling Genetic counseling 
Low cost screening Low cost screening
Additional Brochure: Additional Brochure: 
Improving family support
Suggest genetic counseling Suggest genetic counseling Suggest genetic counseling
Improving family support
Figure 4 Components of the targeted and the enhanced tailored version of the intervention. CA = Cancer.
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interventions require a pre-existing mechanism for
gathering data from the target population [16] they de-
mand more resources making their routine implementa-
tion less likely. The present study will provide information
on the level of variability among hypothesized key
determinants of breast cancer screening, namely, access
barriers and lack of social/family support among YBCS
and their high-risk relatives, and it will allow the compari-
son of the efficacy of each intervention version.
Outcomes
A follow-up survey will be mailed to YBCS and their
high-risk relatives nine months after the baseline survey
to determine the effect of each intervention version on:
a) utilization of breast cancer screening and genetic
counseling; b) perceived barriers and facilitators to
screening; c) self-efficacy in utilizing screening services;
d) family support related to screening; e) knowledge of
the genetics of breast cancer; and f ) satisfaction with the
intervention. Table 2 describes the concepts and
variables of the study (left column), the instruments that
will be used to measure these variables (middle column),
and the assessment times (right column). Instruments
have been previously validated with various populations
(see references in Table 2). Completion of the baseline
and the follow-up questionnaires takes approximately
45 min.
Sample size (power analysis)
Data analyses to meet Aim 3 will require comparison of
randomly assigned subsamples of the entire sample and
make the most demand on the sample size. PASS soft-
ware [28] was used to determine the number of
participants needed to provide 80% power to detect a
medium-small difference (d = 0.3) between means or be-
tween percentages (h = 0.3) using a two-tailed test with
alpha of 0.05. A medium-small effect size (d = 0.3 or h = 0.3)
is a typical effect size found in interventions aiming to in-
crease screening mammography [17,18]. The result of
power analysis was 176 participants per group or 352 in
Table 2 Variables, instruments and assessment times
Concepts/variables Instruments Survivor High-risk relative
Baseline Follow
up
Baseline Follow
up
Knowledge/Attitude
Perceived breast cancer risk Perceived breast cancer risk [11,20] √ √
Knowledge of breast cancer risk factors Breast cancer risk factor knowledge index [11,21] √ √ √ √
Knowledge of breast cancer genetics Knowledge of breast cancer gene inheritance [22] √ √ √ √
Perceived facilitators vs. barriers of
mammography screening
Decisional balance scale for mammography [23,24] √ √ √ √
Subjective norms
Perceived family expectations about breast
cancer screening
Adapted from Ajzen et al. [14] √ √ √ √
Motivation to comply with family members’
expectations
Adapted from Ajzen et al. [14] √ √ √ √
Family support
Perceived family support for breast cancer
screening
Social support for breast cancer screening [25] √ √ √ √
PERCEIVED CONTROL
Self-efficacy in utilizing breast cancer screening
services
Self-efficacy for mammography, CBE, cancer genetic
services [14]
√ √ √ √
Intention
Intention to pursue mammogram, CBE, genetic
counseling (when applicable)
Intention to pursue mammography, CBE, and cancer
genetic services (when applicable) [14]
√ √ √ √
Behavior
Current screening practices Behavioral risk factors surveillance system [24] √ √ √ √
Other
Demographics/personal and family history Behavioral risk factors surveillance system [26] √ √
Breast cancer risk (Gail model) Breast cancer risk assessment tool [27] √ √
Breast cancer risk (Claus model) Claus breast cancer risk tables [13]
Evaluation of the Acceptability of the
Intervention
TBD by researchers √ √
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total. Assuming 35% attrition between baseline and follow
up, 542 participants must be given the intervention to
maintain this level of power. Given the initial target num-
ber for recruitment and the expected response and attri-
tion rates, the study will recruit and maintain a large
enough sample size to perform data analyses for Aim 3
(see Figure 3).
Statistical analyses
Analyses will be conducted separately for YBCS and
high-risk relatives. A descriptive analysis of baseline data
will provide screening utilization practices, perceived
barriers and facilitators to screening, and other
outcomes for YBCS and high-risk relatives. This will in-
clude tabulating counts and frequencies of variables in-
cluding demographics, cancer history, screening history
and perceived breast cancer risk. Bivariate analyses
(using the Chi-square test for differences in proportions
and T-test for differences in means) to assess the
associations between demographic factors, clinical
indications and screening practices will follow. We will
stratify by using the Cochran-Mantel-Haenszel test to
assess the association between family history, screening
practices, genetic counseling/testing, and perceived
facilitators/barriers while controlling separately for race/
ethnicity, age-group, and time since diagnosis. Outcomes
include both continuous and dichotomous measures.
Means and standard deviations will be used to describe
the results. Continuous measures taken only at post-test
will be compared between the two intervention groups
by simple t-tests. After assuming an autocorrelation of
data r = .30, changes over time in continuous measures
will be tested by paired t-tests. For dichotomous
measures taken only at post-test, the rates in the two
groups will be compared by logistic regression. The
proportions in each group will be reported to describe
the results. If a baseline version of the measure is
available, logistic regression will be conducted on the
post-tests with the pre-tests included as covariates. Chi-
square tests will be conducted to test the changes over
time. The above analyses will establish whether the
groups are equivalent, determine whether post-tests dif-
fer between the two groups, and assess the significance
of changes over time. To further meet Aim 3, regression
analyses (linear or logistic) will be used to test which
factors (beyond the intervention) predict obtaining
breast cancer screening.
Discussion
First, this study will expand public health knowledge
about breast cancer surveillance practices among YBCS,
their perceived facilitators and barriers to screening, and
their willingness to advocate for their high-risk female
relatives. Special attention will be given to minority
YBCS. The study will allow us to further understand the
needs of these high-risk women including barriers to
breast cancer screening. Due to random sample selection
and random allocation, study findings can be generalized
to all YBCS and high-risk relatives in the state of
Michigan and possibly to other U.S. states with similar
demographic composition and similar availability and
accessibility of breast cancer screening services. Second,
confirmation of family history will occur simultaneously
with identification of the YBCS in the cancer registry
followed by outreach to her high-risk female relatives.
By circumventing the typical barriers associated with
family history collection (i.e., client awareness of family
history, provider practices regarding family history col-
lection and referral), the study aims to increase breast
cancer screening among women at greatest risk for
breast cancer. This innovative approach of identifying
high-risk women through existing public health data
may lead to a new method of family history collection
and breast cancer risk assessment. Third, this study is
among the first to evaluate two versions (Targeted vs.
Enhanced Tailored) of a printed intervention as a means of
increasing breast cancer screening in YBCS and their high-
risk female relatives. This novel approach will likely expand
our knowledge about interventions that can increase breast
cancer screening among women at substantially higher risk.
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